Mineralys Other Operating Expenses vs Net Interest Income Analysis
| MLYS Stock | 13.11 0.59 4.71% |
Mineralys Therapeutics, financial indicator trend analysis is infinitely more than just investigating Mineralys Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mineralys Therapeutics, is a good investment. Please check the relationship between Mineralys Therapeutics, Other Operating Expenses and its Net Interest Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Other Operating Expenses vs Net Interest Income
Other Operating Expenses vs Net Interest Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mineralys Therapeutics, Other Operating Expenses account and Net Interest Income. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Mineralys Therapeutics,'s Other Operating Expenses and Net Interest Income is 0.98. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Net Interest Income in the same time period over historical financial statements of Mineralys Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Mineralys Therapeutics,'s Other Operating Expenses and Net Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Mineralys Therapeutics, Common are associated (or correlated) with its Net Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Interest Income has no effect on the direction of Other Operating Expenses i.e., Mineralys Therapeutics,'s Other Operating Expenses and Net Interest Income go up and down completely randomly.
Correlation Coefficient | 0.98 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Mineralys Therapeutics,. It is also known as Mineralys Therapeutics, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most indicators from Mineralys Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mineralys Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At this time, Mineralys Therapeutics,'s Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 769.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 130.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 27K | 1.7M | 1.9M | 2.0M | Depreciation And Amortization | 18.7M | 228.5K | 167.9K | 159.5K |
Mineralys Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Mineralys Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.